🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. alvimopan

    Merck KGaA, Darmstadt, Germany

    Constipation

    phase 2 small molecule completed

    1 trial

  2. autologous adipose-derived mesenchymal stem cell transplantation

    Hospital Authority, Hong Kong

    Aging Problems

    phase 2 mab active

    1 trial

  3. avelumab

    Samsung Bioepis NL B.V.

    Lymphoma, Extranodal NK-T-Cell

    phase 2 small molecule active

    1 trial

  4. bomedemstat

    United Therapeutics Europe Ltd

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  5. carbamazepine

    Ultragenyx UK Limited

    Spasms, Infantile

    phase 2 small molecule completed

    1 trial

  6. cemsidomide

    C4 Therapeutics

    Multiple Myeloma

    phase 2 small molecule active

    2 trials

  7. conventional therapy plus low dose hUC-MSCs treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 mab completed

    1 trial

  8. docetaxel

    Sanofi Pasteur

    Nasopharyngeal Neoplasms

    phase 2 small molecule completed

    1 trial

  9. irradiation

    Ultragenyx UK Limited

    Brain Neoplasms

    phase 2 other active

    1 trial

  10. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  11. methylprednisolone

    Teva Pharma GmbH

    Multiple Sclerosis (MS)

    phase 2 small molecule terminated

    1 trial

  12. neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Neoplasms

    phase 2 small molecule completed

    3 trials

  13. nivolumab

    Bristol-Myers Squibb

    Neoplasms by Site

    phase 2 mab completed

    1 trial

  14. oxaliplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  15. pazopanib (GW786034)

    GlaxoSmithKline

    Neoplasms, Uterine Cervix

    phase 2 small molecule completed

    1 trial

  16. pazopanib (GW786034) 400 mg

    GlaxoSmithKline

    Neoplasms, Breast

    phase 2 small molecule completed

    1 trial

  17. rTMS (repetitive transcranial magnetic stimulation)

    CNS Pharmaceuticals

    Obsessive-Compulsive Disorder

    phase 2 other active

    1 trial

  18. rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

    Dompe' Farmaceutici S.p.A.

    Dry Eye

    phase 2 small molecule active

    1 trial

  19. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  20. vistusertib (AZD2014)

    Samsung Bioepis NL B.V.

    Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  21. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  22. A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

    Bristol-Myers Squibb Australia Pty Ltd

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  23. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  24. A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources